{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:58:01Z","timestamp":1777867081968,"version":"3.51.4"},"reference-count":123,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Backgroud: The introduction of highly active immunotherapies has changed the outcome of B-cell non-Hodgkin lymphomas (B-NHLs) in the last two decades. Since then, important progress has been shown using newer and more active immunotherapies, including chimeric antigen receptor T-cell therapy (CAR-T), conjugated monoclonal antibodies, and bispecific antobodies, which currently plays a significant role in the treatment of diffuse large B-cell (DLBCL), follicular (FL), and mantle cell (MCL) lymphoma. Purpose: In this review, we provide an updated overview of recently completed and ongoing BsAb trials in patients with relapsed\/refractory(R\/R) B-NHL and Hodgkin\u2019s lymphoma, including single-agent results, emerging combinations, safety data, and novel constructs. Conclusions: Bispecific antibodies (BsAbs) are a novel class of \u201coff-the-shelf\u201d T-cell-redirecting drugs capable of targeting various cell-surface antigens. New antigen targets are currently under investigation, such as CD19 \u00d7 CD3 and CD30 \u00d7 CD3 or CD30 \u00d7 CD16, in different settings. BsAbs are among the most promising therapeutic options for lymphoma today since they have demonstrated significant single-agent activity, along with a manageable toxicity profile, in patients with heavily pretreated B-NHL.<\/jats:p>","DOI":"10.3390\/cancers17010094","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T12:51:24Z","timestamp":1735822284000},"page":"94","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bispecific Antibodies for Lymphoid Malignancy Treatment"],"prefix":"10.3390","volume":"17","author":[{"given":"Matteo","family":"Bisio","sequence":"first","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Legato","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5591-2686","authenticated-orcid":false,"given":"Filippo","family":"Fasano","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Benevolo Savelli","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Boccomini","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1913-4266","authenticated-orcid":false,"given":"Maura","family":"Nicolosi","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Santambrogio","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6003-3328","authenticated-orcid":false,"given":"Roberto","family":"Freilone","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-3653","authenticated-orcid":false,"given":"Mattia","family":"Novo","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7514-6172","authenticated-orcid":false,"given":"Barbara","family":"Botto","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/CMAR.S400013","article-title":"Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancer Manag. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1019","DOI":"10.1016\/j.clml.2022.07.017","article-title":"Treatment Landscape of Relapsed\/Refractory Mantle Cell Lymphoma: An Updated Review","volume":"22","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.beha.2017.11.003","article-title":"Novel Agents for Relapsed and Refractory Follicular Lymphoma","volume":"31","author":"Cheah","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2022-159702","article-title":"Lisocabtagene Maraleucel (Liso-Cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) as Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study","volume":"140","author":"Abramson","year":"2022","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wang, Q., Chen, Y., Park, J., Liu, X., Hu, Y., Wang, T., McFarland, K., and Betenbaugh, M.J. (2019). Design and Production of Bispecific Antibodies. Antibodies, 8.","DOI":"10.3390\/antib8030043"},{"key":"ref_12","unstructured":"Columvi|European Medicines Agency (EMA) (2024, September 07). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/columvi."},{"key":"ref_13","unstructured":"(2024, September 07). FDA Grants Accelerated Approval to Glofitamab-Gxbm for Selected Relapsed or Refractory Large B-Cell Lymphomas|FDA, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1080\/10428194.2021.1953016","article-title":"Glofitamab CD20-TCB Bispecific Antibody","volume":"62","author":"Minson","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1182\/blood-2023-173949","article-title":"Dexamethasone Is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed\/Refractory (R\/R) Large B-Cell Lymphoma (LBCL)","volume":"142","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rentsch, V., Seipel, K., Banz, Y., Wiedemann, G., Porret, N., Bacher, U., and Pabst, T. (2022). Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. Cancers, 14.","DOI":"10.3390\/cancers14102516"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11864-021-00925-1","article-title":"Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment","volume":"23","author":"Bock","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2021-148778","article-title":"Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (Pts) with Multiple Relapsed or Refractory (R\/R) Follicular Lymphoma (FL)","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2023-174415","article-title":"Incidence of Infections Associated with the Use of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphomas","volume":"142","author":"Fares","year":"2023","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2023-177703","article-title":"Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study","volume":"142","author":"Sesques","year":"2023","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/cncr.35217","article-title":"Glofitamab as a Salvage Treatment for B-Cell Lymphomas in the Real World: A Multicenter Study in Taiwan","volume":"130","author":"Hsu","year":"2024","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1182\/blood-2022-165385","article-title":"Glofitamab in Relapsed\/Refractory Diffuse Large B Cell Lymphoma: Real World Data","volume":"140","author":"Ferhanoglu","year":"2022","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hon.3174","article-title":"Glofitamab in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data","volume":"41","author":"Gulbas","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_27","first-page":"1269","article-title":"Glofitamab Monotherapy Induces High Complete Response Rates and Manageable Safety in Chinese Patients with Heavily Pretreated Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"109","author":"Song","year":"2024","journal-title":"Haematologica"},{"key":"ref_28","unstructured":"(2023, July 09). FDA Grants Accelerated Approval to Mosunetuzumab-Axgb for Relapsed or Refractory Follicular Lymphoma|FDA, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma."},{"key":"ref_29","unstructured":"Lunsumio|European Medicines Agency (EMA) (2024, September 07). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lunsumio."},{"key":"ref_30","unstructured":"Tepkinly|European Medicines Agency (EMA) (2024, September 08). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tepkinly."},{"key":"ref_31","unstructured":"(2024, September 08). FDA Grants Accelerated Approval to Epcoritamab-Bysp for Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma|FDA, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b-cell."},{"key":"ref_32","unstructured":"(2024, September 08). FDA Grants Accelerated Approval to Epcoritamab-Bysp for Relapsed or Refractory Follicular Lymphoma|FDA, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2022-157777","article-title":"Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma","volume":"140","author":"Phillips","year":"2022","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1200\/JCO.2024.42.16_suppl.7008","article-title":"Glofitamab Monotherapy in Patients with Heavily Pretreated Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma (MCL): Updated Analysis from a Phase I\/II Study","volume":"42","author":"Phillips","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2023-173946","article-title":"GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma","volume":"142","author":"Phillips","year":"2023","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1182\/blood-2023-174213","article-title":"Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with \u22652L Relapsed\/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib\/II Study","volume":"142","author":"Hutchings","year":"2023","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2023-174081","article-title":"Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study","volume":"142","author":"Topp","year":"2023","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2023-173953","article-title":"Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (CtDNA) Dynamics: Preliminary Safety and Efficacy Results","volume":"142","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"ref_39","unstructured":"(2024, June 28). Glofitamab\u25bc Plus Gemcitabine and Oxaliplatin (GLOFIT-GEMOX) for Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Global Randomized Phase III Trial (STARGLO)\u2014EHA-2024-Presentation-Abramson-Glofitamab-plus-Gemcitabine.Pdf. Available online: https:\/\/medically.roche.com\/global\/en\/haematology\/eha-2024\/medical-material\/EHA-2024-presentation-abramson-glofitamab-plus-gemcitabine-pdf.html."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2023-188854","article-title":"Feasibility and Safety of the First-in-Human Chemotherapy-Light Combination of Rituximab, Polatuzumab Vedotin and Glofitamab in Previously Untreated Aggressive B-Cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP\u2014R-Pola-Glo\/Ikf-T062, a Study of the Austrian Group for Medical Tumor Therapy (AGMT-NHL-16) and the German Lymphoma Alliance (GLA2022-10)","volume":"142","author":"Melchardt","year":"2023","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2023023381","article-title":"CD19-CD28: An Affinity-Optimized CD28 Agonist for Combination with Glofitamab (CD20-TCB) as off-the-Shelf Immunotherapy","volume":"143","author":"Sam","year":"2024","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1182\/blood-2023-182275","article-title":"A Multicenter, Open-Label, Phase 1b\/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma","volume":"142","author":"Luscan","year":"2023","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable Responses with Mosunetuzumab in Relapsed\/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I\/II Study","volume":"42","author":"Budde","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/blood-2023-173692","article-title":"Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and\/or Refractory Follicular Lymphoma after \u22652 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study","volume":"142","author":"Schuster","year":"2023","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and Efficacy of Mosunetuzumab, a Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-Arm, Multicentre, Phase 2 Study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2022-157729","article-title":"Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (Pts) with Relapsed\/Refractory (R\/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I\/II Study","volume":"140","author":"Budde","year":"2022","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab Monotherapy Is Active and Tolerable in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2023-187911","article-title":"Infectious Complications in Patients with Relapsed or Refractory (R\/R) Non-Hodgkin\u2019s Lymphoma (NHL) Treated with the Anti-CD20 \u00d7 CD3 Bispecific Antibody (BsAb) Mosunetuzumab","volume":"142","author":"Shahid","year":"2023","journal-title":"Blood"},{"key":"ref_51","unstructured":"(2024, June 28). Mosunetuzumab\u25bc Demonstrates Clinically Meaningful Outcomes in High-Risk Patients with Heavily Pre-Treated R\/R FL after \u22653 Years of Follow-Up: Subgroup Analysis of a Pivotal Phase II Study\u2014EHA-2024-Presentation-Assouline-Mosunetuzumab-Demonstrates-Clinically.Pdf. Available online: https:\/\/medically.roche.com\/global\/en\/haematology\/eha-2024\/medical-material\/EHA-2024-presentation-assouline-mosunetuzumab-demonstrates-clinically-pdf.html."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 Expression as a Mechanism of Resistance to Mosunetuzumab in Relapsed\/Refractory B-Cell Lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1182\/blood-2022-157768","article-title":"Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly\/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2023-174292","article-title":"Early Complete Responses with Mosunetuzumab Monotherapy in Treatment-Na\u00efve Follicular and Marginal Zone Lymphomas with Only Low-Grade Cytokine Release Syndrome","volume":"142","author":"Lynch","year":"2023","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1182\/blood-2023-177917","article-title":"Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study","volume":"142","author":"Flinn","year":"2023","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2023-179906","article-title":"Subcutaneous (SC) Mosunetuzumab (Mosun) As First-Line Therapy for Patients (Pts) with High Tumor-Burden Follicular Lymphoma (FL): First Results of a Multicenter Phase 2 Study","volume":"142","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2023-173796","article-title":"Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter\u2019s Transformation","volume":"142","author":"Cheah","year":"2023","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed\/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2023-174432","article-title":"Preliminary Findings of a Phase Ib\/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood-2023-180473","article-title":"Marsun, a Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma (R\/R MZL)","volume":"142","author":"Thieblemont","year":"2023","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in Combination with CHOP in Previously Untreated DLBCL: Safety and Efficacy Results from a Phase 2 Study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with Polatuzumab Vedotin in Relapsed or Refractory Aggressive Large B Cell Lymphoma: A Phase 1b\/2 Trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2023-177588","article-title":"Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit\/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"142","author":"Olszewski","year":"2023","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed\/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib\/II Study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose Escalation of Subcutaneous Epcoritamab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: An Open-Label, Phase 1\/2 Study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell\u2013Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-021-00430-6","article-title":"Epcoritamab Induces Potent Anti-Tumor Activity against Malignant B-Cells from Patients with DLBCL, FL and MCL, Irrespective of Prior CD20 Monoclonal Antibody Treatment","volume":"11","author":"Hiemstra","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-133820","article-title":"Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope Interactions of Monoclonal Antibodies Targeting CD20 and Their Relationship to Functional Properties","volume":"5","author":"Klein","year":"2013","journal-title":"mAbs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/cpt.2729","article-title":"Semimechanistic Physiologically-Based Pharmacokinetic\/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients with B-Cell Lymphomas","volume":"112","author":"Li","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"E593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE NHL-1): A Phase 2 Cohort of a Single-Arm, Multicentre Study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2022-158298","article-title":"Subcutaneous Epcoritamab in Patients with Richter\u2019s Syndrome: Early Results from Phase 1b\/2 Trial (EPCORE CLL-1)","volume":"140","author":"Kater","year":"2022","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1182\/blood-2022-158245","article-title":"Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed\/Refractory (R\/R) Large B-Cell Lymphoma (LBCL)","volume":"140","author":"Phillips","year":"2022","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1182\/blood-2022-158278","article-title":"Subcutaneous Epcoritamab + R-Dhax\/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1\/2 Results","volume":"140","author":"Abrisqueta","year":"2022","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2022-158203","article-title":"Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1\/2 Trial Update","volume":"140","author":"Falchi","year":"2022","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1182\/blood-2022-158232","article-title":"Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1\/2 Trial","volume":"140","author":"Falchi","year":"2022","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2023-180246","article-title":"Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2","volume":"142","author":"Brody","year":"2023","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood-2023-180935","article-title":"Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial","volume":"142","author":"Vermaat","year":"2023","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/blood-2023-180089","article-title":"Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5","volume":"142","author":"Kim","year":"2023","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-024-00989-w","article-title":"Bi- and Tri-Specific Antibodies in Non-Hodgkin Lymphoma: Current Data and Perspectives","volume":"14","author":"Dulery","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a Human CD20\u00d7CD3 Bispecific Antibody in Patients with CD20-Positive B-Cell Malignancies (ELM-1): Results from the Relapsed or Refractory Non-Hodgkin Lymphoma Cohort in a Single-Arm, Multicentre, Phase 1 Trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1182\/blood-2023-181602","article-title":"Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study","volume":"142","author":"Crombie","year":"2023","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2023-179818","article-title":"Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2023-181650","article-title":"Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed\/Refractory (R\/R) Follicular Lymphoma (FL) with Extended Follow-Up","volume":"142","author":"Villasboas","year":"2023","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"eabn1082","DOI":"10.1126\/scitranslmed.abn1082","article-title":"CD22-Targeted CD28 Bispecific Antibody Enhances Antitumor Efficacy of Odronextamab in Refractory Diffuse Large B Cell Lymphoma Models","volume":"14","author":"Wei","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1182\/blood-2022-159586","article-title":"A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma: Recommended Dose Safety\/Efficacy Update and Escalation Exposure-Response Analysis","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"ref_87","first-page":"153","article-title":"Antibody Therapies for Large B-Cell Lymphoma","volume":"15","author":"Novo","year":"2021","journal-title":"Biologics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2019-131650","article-title":"High Avidity IgM-Based CD20 \u00d7 CD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release","volume":"134","author":"Baliga","year":"2019","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2021-153355","article-title":"A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1182\/blood-2022-163235","article-title":"Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20 \u00d7 CD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies","volume":"140","author":"Hernandez","year":"2022","journal-title":"Blood"},{"key":"ref_91","first-page":"228","article-title":"Biological Activity Validation of a Computationally Designed Rituximab\/CD3 T Cell Engager Targeting CD20+ Cancers with Multiple Mechanisms of Action","volume":"4","author":"Cai","year":"2021","journal-title":"Antib. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood-2023-188444","article-title":"GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20\/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety\/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma","volume":"142","author":"Song","year":"2023","journal-title":"Blood"},{"key":"ref_93","unstructured":"Blincyto|European Medicines Agency (EMA) (2024, September 08). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/blincyto."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: A Historical Perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-Term Outcome of Patients with Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma Treated with Blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 Study of the Bispecific T-Cell Engager (BiTE) Antibody Blinatumomab in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-Label, Phase 2 Study of Blinatumomab as Second Salvage Therapy in Adults with Relapsed\/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/blood-2021-152822","article-title":"A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed\/Refractory (R\/R) Indolent Non Hodgkin\u2019s Lymphoma (NHL)","volume":"138","author":"Rossi","year":"2021","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/10428194.2022.2064981","article-title":"Open-Label, Phase 2 Study of Blinatumomab after Frontline R-Chemotherapy in Adults with Newly Diagnosed, High-Risk DLBCL","volume":"63","author":"Katz","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1182\/bloodadvances.2023011130","article-title":"Blinatumomab Consolidation Post\u2013Autologous Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma","volume":"8","author":"Ghobadi","year":"2024","journal-title":"Blood Adv."},{"key":"ref_102","first-page":"e19584","article-title":"Results from a Phase 1b Study of Blinatumomab-Pembrolizumab Combination in Adults with Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"40","author":"Giri","year":"2022","journal-title":"ASCO"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Benevolo Savelli, C., Bisio, M., Legato, L., Fasano, F., Santambrogio, E., Nicolosi, M., Morra, D., Boccomini, C., Freilone, R., and Botto, B. (2024). Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice. Cancers, 16.","DOI":"10.3390\/cancers16101830"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/2326-6066.CIR-17-0550","article-title":"CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells","volume":"6","author":"Pahl","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a Bispecific CD30\/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A Phase 1 Study of the Bispecific Anti-CD30\/CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2019004701","article-title":"A Phase 1b Study of AFM13 in Combination with Pembrolizumab in Patients with Relapsed or Refractory Hodgkin Lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140096","article-title":"Clinical and Biological Evaluation of the Novel CD30\/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib\/IIa Study (NCT03192202)","volume":"136","author":"Sawas","year":"2020","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"CT024","DOI":"10.1158\/1538-7445.AM2023-CT024","article-title":"REDIRECT: A Phase 2 Study of AFM13 in Patients with CD30-Positive Relapsed or Refractory (R\/R) Peripheral T Cell Lymphoma (PTCL)","volume":"83","author":"Kim","year":"2023","journal-title":"Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2023-172980","article-title":"Innate Cell Engager (ICE\u00ae) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results","volume":"142","author":"Nieto","year":"2023","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1182\/blood-2023-174250","article-title":"AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)","volume":"142","author":"Moskowitz","year":"2023","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1182\/blood-2022-159396","article-title":"Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies","volume":"140","author":"Oostindie","year":"2022","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1225610","DOI":"10.3389\/fimmu.2023.1225610","article-title":"Novel Anti-CD30\/CD3 Bispecific Antibodies Activate Human T Cells and Mediate Potent Anti-Tumor Activity","volume":"14","author":"Faber","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1182\/blood-2023-188071","article-title":"Safety and Efficacy of A-319 (a CD3xCD19 T Cell Engager) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"},{"key":"ref_116","unstructured":"Morschhauser, F., Gritti, G., Dickinson, M., Hutchings, M., Bosch, F., Townsend, W., Bartlett, N.L., Cartron, G., Ghesquieres, H., and Houot, R. (2024, January 13\u201316). Englumafusp Alfa (CD19\/4-1BBL) Combined with Glofitamab Is Safe and Shows High Efficacy in Patients with R\/R Aggressive B-NHL: Final Results of the Dose Escalation Part of Phase 1 Trial BP41072. Proceedings of the 2024 European Hematology Association (EHA) Annual Meeting, Borovets, Bulgaria. ASH Abstracts."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2023-173677","article-title":"Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma (R\/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial","volume":"142","author":"Korr","year":"2023","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41375-022-01805-9","article-title":"IMM0306, a Fusion Protein of CD20 MAb with the CD47 Binding Domain of SIRP\u03b1, Exerts Excellent Cancer Killing Efficacy by Activating Both Macrophages and NK Cells via Blockade of CD47-SIRP\u03b1 Interaction and Fc\u0263R Engagement by Simultaneously Binding to CD47 and CD20 of B Cells","volume":"37","author":"Yu","year":"2022","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1182\/blood-2022-157862","article-title":"Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (MAb-Trap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin\u2019s Lymphoma (R\/R B-NHL)","volume":"140","author":"Shi","year":"2022","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41590-023-01671-2","article-title":"CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity","volume":"24","author":"Tang","year":"2023","journal-title":"Nat. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood-2022-166385","article-title":"Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed\/Refractory (R\/R) B-NHL","volume":"140","author":"Hou","year":"2022","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2023-174668","article-title":"Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed\/Refractory (R\/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial","volume":"142","author":"Gaballa","year":"2023","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"100783","DOI":"10.1016\/j.xcrm.2022.100783","article-title":"Antitumor Immunity Induced by Antibody-Based Natural Killer Cell Engager Therapeutics Armed with Not-Alpha IL-2 Variant","volume":"3","author":"Demaria","year":"2022","journal-title":"Cell Rep. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/94\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:57:31Z","timestamp":1760115451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/94"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":123,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17010094"],"URL":"https:\/\/doi.org\/10.3390\/cancers17010094","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}